{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T21:08:20Z","timestamp":1785186500425,"version":"3.55.0"},"reference-count":13,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":1608,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,5]]},"DOI":"10.1111\/j.1365-2265.2010.03973.x","type":"journal-article","created":{"date-parts":[[2010,12,30]],"date-time":"2010-12-30T13:07:31Z","timestamp":1293714451000},"page":"608-610","source":"Crossref","is-referenced-by-count":32,"title":["Cardiac valve disease and low-dose dopamine agonist therapy: an artefact of reporting bias?"],"prefix":"10.1111","volume":"74","author":[{"given":"Haotian","family":"Gu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Luck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul V.","family":"Carroll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jake","family":"Powrie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Chambers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2011,4,7]]},"reference":[{"key":"10.1111\/j.1365-2265.2010.03973.x-BIB1|cit1","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1056\/NEJMcp043908","article-title":"Diagnosis and initial management of Parkinson\u2019s diease","volume":"353","author":"Nutt","year":"2005","journal-title":"New England Journal of Medicine"},{"key":"10.1111\/j.1365-2265.2010.03973.x-BIB2|cit2","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1056\/NEJMoa054830","article-title":"Valvular heart disease and the use of dopamine agonists for Parkinson\u2019s disease","volume":"356","author":"Zanettini","year":"2007","journal-title":"New England Journal of Medicine"},{"key":"10.1111\/j.1365-2265.2010.03973.x-BIB3|cit3","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1056\/NEJMoa062222","article-title":"Dopamine agonists and the risk of cardiac-valve regurgitation","volume":"356","author":"Schade","year":"2007","journal-title":"New England Journal of Medicine"},{"key":"10.1111\/j.1365-2265.2010.03973.x-BIB4|cit4","volume-title":"EMEA Recommends New Warnings and Contraindications for Ergot-Derived Dopamine Agonists","author":"European Medicines Agency","year":"2008"},{"key":"10.1111\/j.1365-2265.2010.03973.x-BIB5|cit5","doi-asserted-by":"crossref","first-page":"3777","DOI":"10.1210\/jc.2007-1403","article-title":"Increased prevalence of tricuspid regurgitation in patients with prolactinomas chronically treated with cabergoline","volume":"93","author":"Colao","year":"2007","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"10.1111\/j.1365-2265.2010.03973.x-BIB6|cit6","doi-asserted-by":"crossref","first-page":"3348","DOI":"10.1210\/jc.2007-2658","article-title":"Aortic valve calcification and mild tricuspid regurgitation, but no clinical heart disease after 8\u2003years of dopamine agonist therapy for prolactinoma","volume":"93","author":"Kars","year":"2008","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"10.1111\/j.1365-2265.2010.03973.x-BIB7|cit7","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1111\/j.1742-1241.2008.01779.x","article-title":"Treatment with low doses of cabergoline is not associated with increased prevalence of cardiac valve regurgitation in patients with hyperprolactinaemia","volume":"62","author":"Bogazzi","year":"2008","journal-title":"International Journal of Clinical Practice"},{"key":"10.1111\/j.1365-2265.2010.03973.x-BIB8|cit8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1530\/EJE-08-0213","article-title":"Cabergoline and the risk of valvular lesions in endocrine disease","volume":"159","author":"Lancellotti","year":"2008","journal-title":"European Journal of Endocrinology"},{"key":"10.1111\/j.1365-2265.2010.03973.x-BIB9|cit9","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/s11102-008-0134-2","article-title":"Long-term cabergoline therapy is not associated with valvular heart disease in patients with prolactinomas","volume":"12","author":"Vallette","year":"2009","journal-title":"Pituitary"},{"key":"10.1111\/j.1365-2265.2010.03973.x-BIB10|cit10","doi-asserted-by":"crossref","first-page":"R11","DOI":"10.1530\/EJE-08-0365","article-title":"Low dose cabergoline for hyperprolactinaemia is not associated with clinically significant valvular heart disease","volume":"159","author":"Wakil","year":"2008","journal-title":"European Journal of Endocrinology"},{"key":"10.1111\/j.1365-2265.2010.03973.x-BIB11|cit11","first-page":"438","article-title":"European association of echocardiography recommendations for standardization of performance, digital storage and reporting of echocardiographic studies","volume":"9","author":"Popescu","year":"2009","journal-title":"European Journal of Echocardiography"},{"key":"10.1111\/j.1365-2265.2010.03973.x-BIB12|cit12","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/S0894-7317(03)00335-3","article-title":"Recommendations for evaluation of the severity of native valvular regurgitation with two-dimensional and Doppler echocardiography","volume":"16","author":"Zoghbi","year":"2003","journal-title":"Journal of American Society of Echocardiography"},{"key":"10.1111\/j.1365-2265.2010.03973.x-BIB13|cit13","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1111\/j.1365-2265.2010.03827.x","article-title":"Assessment of cardiac valve dysfunction in patients receiving cabergoline treatment for hyperprolactinaemia","volume":"73","author":"Tan","year":"2010","journal-title":"Clinical Endocrinology"}],"container-title":["Clinical Endocrinology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2265.2010.03973.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/j.1365-2265.2010.03973.x\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,13]],"date-time":"2021-02-13T08:16:50Z","timestamp":1613204210000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1111\/j.1365-2265.2010.03973.x"}},"subtitle":["Valve disease on low-dose dopamine agonist therapy"],"short-title":[],"issued":{"date-parts":[[2011,4,7]]},"references-count":13,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2011,5]]}},"URL":"https:\/\/doi.org\/10.1111\/j.1365-2265.2010.03973.x","relation":{},"ISSN":["0300-0664"],"issn-type":[{"value":"0300-0664","type":"print"}],"subject":[],"published":{"date-parts":[[2011,4,7]]}}}